Discuss a project

Frequently Asked Questions.

Discuss a project

Upperton provides integrated CDMO services from pre-clinical development through Phase I and II clinical supplies, Phase III process scale-up, registration batches and commercial manufacturing. This enables continuity throughout development without the need to transfer projects between multiple suppliers.

Our expertise includes oral solid dosage forms, nasal products, pulmonary delivery systems and sterile parenteral products. We support formulation development, analytical development and GMP manufacturing across these delivery routes.

Yes. We have extensive experience developing formulations for poorly soluble compounds and utilise enabling technologies including spray drying and amorphous solid dispersions to improve solubility, dissolution and bioavailability. Our UpperSolv™ development platform helps identify the most effective formulation strategy early in development.

Our development teams consider scale-up and commercialisation requirements from the outset. Process development, pilot-scale manufacturing and technical transfer activities are designed to minimise risk and ensure smooth progression from early development through late-phase manufacturing and commercial supply

Upperton provides analytical method development, validation, stability testing, release testing and ongoing QC support. Our analytical teams develop phase-appropriate methods and generate data packages to support regulatory submissions and commercial manufacture

Yes. Our regulatory affairs specialists support product development programmes with CMC documentation, submission strategies, registration activities and technical support for regulatory interactions, helping accelerate development while maintaining compliance.

Projects are managed through dedicated project management teams that coordinate technical, analytical, manufacturing and regulatory activities. Our integrated development model provides a single point of contact and clear communication throughout the programme.

Upperton operates a sterile fill-finish manufacturing facility aligned to current regulatory expectations and supports small-scale sterile manufacturing programmes. These capabilities are ideal for clinical-stage products and specialist formulations requiring aseptic processing.

The earlier a CDMO is engaged, the greater the opportunity to de-risk development. Early involvement enables formulation strategy selection, manufacturability assessments, analytical planning and scale-up considerations to be incorporated before significant development milestones are reached.

Upperton combines scientific expertise with a flexible and collaborative approach. Unlike many larger organisations, projects are not treated as commodity programmes. Clients benefit from direct access to technical experts, responsive project management and integrated development and manufacturing services delivered from a single site.

Yes. Upperton supports the development and manufacture of complex drug products, including challenging molecules that require specialist handling, containment and formulation expertise. Our scientific teams assess potency, exposure limits, formulation requirements and manufacturing controls to develop a suitable programme that protects both product quality and operator safety while maintaining development efficiency.

Yes. We support late-stage development programmes through Phase III scale-up, registration batch manufacture and validation activities. Our teams work with sponsors to generate the required process, analytical and stability data to support regulatory submissions and commercial readiness.

Our approach to technology transfer begins during development. Process understanding, critical quality attributes and manufacturing parameters are documented throughout the programme to ensure knowledge is retained and transferable. Dedicated technical and project management teams coordinate activities to minimise risk, maintain timelines and ensure a smooth transition between development and manufacturing stages.